Effect of Imeglimin on muscle sympathetic nerve activiy in type 2 diabetes mellitus patients

Takamura Masayuki0 个研究点目标入组 30 人开始时间: 2022年5月28日最近更新: 2023年10月17日

试验速览

暂无简介。

•1) Age 20 to 80 years old
•2) Patients diagnosed with type 2 diabetes
•3) HbA1c> 7% and <10% patients
•4) Patients who received sufficient explanation before participating in this study, and who obtained the patient's free will to consent to the document after sufficient understanding.

•1) Patients with a history of stroke or vascular replacement surgery
•2) Patients who develop myocardial infarction within 3 months
•3) Patients with acute coronary syndrome
•4) Patients receiving drug therapy for serious lung diseases such as interstitial pneumonia
•5) Patients with organic heart disease such as severe valvular disease and shunt disease
•6) Patients with moderate renal dysfunction (eGFR<45 ml / min / 1.73 m2) or hepatic dysfunction (PT activity <80%)
•7) Patients suspected of being involved in secondary diabetes (endocrine, drug-induced, cirrhosis, e
•8) Compromised patients such as immunocompromised patients
•9) Patients with a history or complication of ketoacidosis, diabetic coma or precoma
•10) Patients with a history of severe hypoglycemic symptoms with coma or loss of consciousness, or
•patients with hypoglycemic symptoms (more than twice a week) in the last 8 weeks
•11) Patients suspected of alcohol or substance abuse
•12) Pregnant or potentially pregnant patients, or lactating patients
•13) Patients being treated for malignant tumors
•14) Patients with a history of hypersensitivity to imeglimin hydrochloride
•15) Patients participating in other clinical trials
•16) Other patients who are judged by the investigator (sharing) to be inappropriate as subjects

发起方

Takamura Masayuki